Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3

Cheng-Shi He¹ Yi-Cheng Liu² Zhi-Peng Xu³ Peng-Chen Dai⁴ Xiao-Wei Chen⁵ De-Hai Jin⁶

¹Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ²Department of ICU, Pengzhou Hospital of Traditional Chinese Medicine, Pengzhou, ³Pengzhou Hospital of Traditional Chinese Medicine, Pengzhou, ⁴Chengdu University of Traditional Chinese Medicine, Chengdu, ⁵Pengzhou Hospital of Traditional Chinese Medicine, Pengzhou, ⁶Department of Respiration, Pengzhou Hospital Of Traditional Chinese Medicine, Pengzhou, China

Key Word
Non-small cell lung cancer • Chemoresistance • Astragaloside IV • B7-H3

Abstract
Background: Chemoresistance is a major obstacle to successful chemotherapy for human non-small cell lung cancer (NSCLC). Astragaloside IV, the component of Astragalus membranaceus, has been reported to exhibit anti-inflammation, anti-cancer and immunoregulatory properties. In the present study, we investigated the role of astragaloside IV in the chemoresistance to cisplatin in NSCLC cells. Methods: We established astragaloside IV-suppressed NSCLC cell lines including A549, HCC827, and NCI-H1299 and evaluated their sensitivity to cisplatin in vitro. In addition, we examined the mRNA and protein levels of B7-H3 in response to cisplatin-based chemotherapy. Results: We showed that high doses of astragaloside IV (10, 20, 40 ng/ml) inhibited NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/ml) had no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increased chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibited the mRNA and protein levels of B7-H3 in the presence of cisplatin. In addition, ectopic expression of B7-H3 diminished the sensitization role of astragaloside IV in cellular responses to cisplatin in NSCLC cells. Conclusion: These results demonstrate that astragaloside IV enhances chemosensitivity to cisplatin via inhibition of B7-H3 and that treatment with astragaloside IV and inhibition of B7-H3 serve as potential therapeutic approach for lung cancer patients.

C.-S. He and Y.-C. Liu contributed equally to this work.

Yi-Cheng Liu
Department of ICU, Pengzhou Hospital of Traditional Chinese Medicine, 396 South Street, Pengzhou, 611930 (China)
Tel. +86-013547913664, E-Mail lyichengl@sina.com
Introduction

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide with a lower overall 5-year survival rate compared with other types of cancer [1]. Availability of treatment strategies for NSCLC includes conventional surgery, radiotherapy, immunotherapy, chemotherapy, and a combination of these therapies [2, 3]. However, resistance to anti-cancer agents has become a great challenge for NSCLC treatment. Thus, it is important to focus on cancer-specific molecular changes and develop new and effective targeted therapies in clinical practice.

B7-H3, a member of the B7 family, is broadly expressed on transcriptional level in lymphoid and nonlymphoid organs and complicates the immune response by regulation of co-stimulatory and co-inhibitory pathways [4, 5]. Several studies have suggested that B7-H3 is also present in certain types of human cancer and plays critical roles in carcinogenesis and tumor progression [6]. Up-regulation of B7-H3 occurs in a wide range of cancers, such as prostate cancer, lung cancer, colorectal carcinoma, pancreatic cancer, ovarian carcinoma and gastric cancer [7-12]. These observations demonstrate that overexpression of B7-H3 may indicate an aggressive biologic role in carcinogenesis. Accordingly, inhibition of B7-H3 expression effectively suppresses tumor cell growth, migration and metastasis, suggesting that B7-H3 is a potential therapeutic target in cancer treatment [13, 14].

Astragalus membranaceus is commonly used in Traditional Chinese Medicine to treat a variety of diseases [15]. Astragaloside IV, the component of Astragalus membranaceus, exhibits anti-oxidant, anti-cancer and neuro-protective properties [16]. In the current study, we investigated the tumor suppressive effects of astragaloside IV combined with B7-H3 in NSCLC cells.

Materials and Methods

Cell culture and reagents

The human NSCLC cell lines including A549, HCC827, and NCI-H1299 were purchased from the ATCC (Manassas, VA, USA). Astragaloside IV and cisplatin were purchased from Sigma-Aldrich (St. Louis, MO, USA). All cells were maintained at 37°C in 5% CO₂ incubator and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in an atmosphere containing 5% CO₂ at 37 °C.

Cell viability

Cell viability was determined by CCK-8 assay. To be brief, cultured NSCLC cells were seeded into 96-well plates at the density of 4 x 10⁴ (cells/well). Then 10 µL / well CCK8 solution (Beyotime, Nantong, China) was added and incubated in dark at 37 °C for another 2 h. The absorbance was determined with the wavelength of 490 nm.

Apoptosis rate was measured by flow cytometry (FCM) analysis using propidium iodide (PI) apoptosis detection. To be brief, after treatment with cisplatin alone or in combination with astragaloside IV, the three human cell lines were washed with PBS, suspended by trypsinization, harvested by centrifugation (4 °C, 3000 RPM, 5 min) and resuspended in 400 μl binding buffer at a concentration of 9 x 10⁵ cells/ml, and then 10 μl PI was added into the above solution for 5 min in dark (4 °C) before a further addition of 600 μl PBS. Apoptosis rate was assessed by FCM analysis and 10,000 events were recorded for each FCM analysis.

Plasmid construction and transfection

The cDNA fragment encoding B7-H3 was isolated with Takara RNA PCR kit (Takara, Japan) using total RNAs. PCR products were cloned into pcDNA3.1 (+) (Invitrogen, Carlsbad, CA). Cells were transfected with plasmid encoding B7-H3 using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. The transfection medium (Opti-MEM; Gibco) was replaced with complete medium 12 h after transfection, and the cells were incubated for the indicated times.

Real-time PCR
Total RNAs were isolated from tissues or cells by TRIzol reagent, and reverse transcriptions were performed by Takara RNA PCR kit (Takara, Japan) according to the manufacturer's instructions. In order to quantify the transcripts of the interest genes, real-time PCR was performed using a SYBR Green Premix Ex Taq (Takara, Tokyo, Japan) on ABI 7500 system (Applied Biosystems, Foster, CA, USA) with GAPDH used as the endogenous control.

**Western blot**

Cells were lysed with RIPA lysis buffer (Beyotime, Nantong, China), and protein concentration was quantified with Pierce BCA Protein Assay Kit (Thermo, USA). Protein samples were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). The membranes were then incubated with anti-B7-H3 (Cell Signaling Technology, USA) antibodies at 4°C overnight. The membranes were washed three times with TBST prior to incubation with the appropriate HRP-conjugated secondary antibodies (Cell Signaling Technology, USA). The membranes were detected by chemiluminescence (GE Healthcare, Piscataway, NJ, USA).

**Statistical analysis**

Each experiment was performed in triplicate, and repeated at least three times. All the data were presented as means ± SD and treated for statistics analysis by SPSS program. Comparison between groups was made using ANOVA and P < 0.05 was considered to indicate a statistically significant result.

**Results**

**Effects of astragaloside IV on NSCLC cell viability**

In order to determine the cytotoxic effects of astragaloside IV on NSCLC cells, CCK-8 assay was performed in three NSCLC cell lines exposed to astragaloside IV and cisplatin in different concentrations ranging from 0~40 ng/ml. Results showed that low doses of astragaloside IV (1, 2.5, 5 ng/ml) and cisplatin (0.5, 1, 2.5 μM) had no obvious cytotoxicity in A549, HCC827, and NCI-H1299 cells. However, higher concentrations of astragaloside IV (10, 20, 40 ng/ml) and cisplatin (5, 10, 20, 40 μM) significantly reduced the viability of NSCLC cells (Fig. 1A-D).

**Combined treatment with astragaloside IV and cisplatin induce apoptosis in NSCLC cells**

We next used FCM analysis with PI staining to determine whether treatment with cisplatin alone or in combination with astragaloside IV induced apoptosis. Results showed
that treatment with 2.5 μM of cisplatin alone had no obvious apoptosis in A549, HCC827, and NCI-H1299 cells. However, after treatment with combination with 2.5 μM of cisplatin and 5 ng/mL astragaloside IV, the percentage of apoptotic cells increased to 39.57 %, 36.77 %, 34.85 % in A549, HCC827, and NCI-H1299 cells, respectively. (Fig. 2)

**Combined treatment with astragaloside IV sensitizes NSCLC cells to cisplatin**

Next, 5 ng/ml of astragaloside IV was chosen to examine its role in 2.5 μM of cisplatin sensitivity in NSCLC cells. CCK-8 assay indicated that combined treatment with astragaloside IV
He et al.: Astragaloside IV Enhances Chemosensitivity to Cisplatin in NSCLC

Astragaloside IV and cisplatin remarkably inhibited A549 cell viability compared with cisplatin-treated cells alone (Fig. 2A). In addition, similar cisplatin-sensitive role of astragaloside IV was also observed in HCC827 (Fig. 2B) and NCI-H1299 (Fig. 2C) cells. Taken together, these data suggest that astragaloside IV sensitizes NSCLC cells to cisplatin treatment.

Co-treatment with astragaloside IV and cisplatin induce apoptosis in NSCLC cells

We next used FCM analysis with PI staining to determine whether treatment with cisplatin alone or in combination with astragaloside IV induced apoptosis. Results showed that treatment with 2.5 μM of cisplatin alone had no obvious apoptosis in A549, HCC827, and NCI-H1299 cells. However, after treatment with combination with 2.5 μM of cisplatin and 5 ng/mL astragaloside IV, the percentage of apoptotic cells increased to 39.57 %, 36.77 %, 34.85 % in A549, HCC827, and NCI-H1299 cells, respectively. (Fig. 3)

Co-treatment with astragaloside IV and cisplatin inhibits B7-H3 expression

In order to elucidate the mechanism underlying the sensitization role of astragaloside IV, we examined the molecular changes in NSCLC cells before and after astragaloside IV co-treatment. Real time PCR showed that the mRNA expression of B7-H3 was significantly inhibited in A549 cells after co-administration with astragaloside IV (Fig. 4A). Moreover, combined treatment with astragaloside IV suppressed the protein expression of B7-H3 in A549 cells compared with the cisplatin-treated cells (Fig. 4C). In addition, the similar inhibitive effect of astragaloside IV on B7-H3 expression was also observed in HCC827 cells both on the mRNA and protein levels (Fig. 4B and D). These results imply that astragaloside IV sensitizes NSCLC cells to cisplatin through inhibition of B7-H3.
B7-H3 overexpression diminished the role of astragaloside IV in the sensitization to cisplatin

To determine the role of B7-H3 in the chemoresistance, we constructed the plasmid encoding B7-H3 and transfected it into A549 cells. Real time PCR showed that the mRNA expression of B7-H3 increased more than three-folds in B7-H3 plasmid-tranfected cells. ** P < 0.01 was compared to control, ## P < 0.01 was compared to cisplatin group.
Fig. 5A. Furthermore, the protein expression of B7-H3 was obviously increased in A549 cells transfected with plasmid encoding B7-H3 (Fig. 5B and C). As a result, we found that ectopic expression of B7-H3 diminished the sensitization role of astragaloside IV in cellular response to cisplatin (Fig. 5D). In addition, the similar effects of B7-H3 overexpression on the sensitization role of astragaloside IV in cellular response to cisplatin were also observed in HCC827 cells both on the mRNA and protein levels (Fig. 6 and Fig. 7). Taken together, these results demonstrate that astragaloside IV enhances the cisplatin cytotoxicity via regulation of B7-H3 in NSCLC cells.

**Discussion**

Acquisition of resistance to chemotherapeutic agents is a major cause of treatment failure during clinical treatment of malignant cells [17, 18]. Development of potential anti-cancer drugs from traditional Chinese medicine is among the most important strategies in the field of cancer chemotherapy. In the current study, we found that astragaloside IV could potentiate the cisplatin cytotoxicity through inhibition of B7-H3 in NSCLC cells.

Astragaloside IV is a main component of *Astragalus membranaceus*, a commonly used medicinal plant in East Asia [19]. Previous studies have reported that astragaloside IV is a novel anti-inflammatory agent and may be used for the treatment of cardiovascular diseases [20]. Moreover, astragaloside II has been proved to be capable of reversing hepatoma multiple drug resistance through inhibition of mdr1 expression and mitogen-activated protein kinase (MAPK) signals [21]. In the current study, our results showed that high doses of astragaloside IV inhibited NSCLC cell growth, whereas low concentrations of astragaloside IV had no obvious cytotoxicity in A549, HCC827, and NCI-H1299 cells. In addition, we firstly found that combined treatment with astragaloside IV significantly increased the cisplatin...
sensitivity in NSCLC cells, suggesting the potential clinical application of astragaloside IV on patients resistant to anti-cancer agents.

B7-H3 was originally cloned from a dendritic cell cDNA library and is expressed at low levels in several normal lymphoid and peripheral tissues [22,23]. Recently, numerous studies have revealed that B7-H3 is abnormally upregulated in a variety of cancers, whereas the B7-H4 protein is barely detected in the majority of normal human tissues [24,25]. In addition, overexpression of B7-H3 has been suggested to be positively correlated with tumor size, progression and prognosis [25]. For instance, Zang et al. and Roth et al. showed that B7-H3 is abundantly expressed in prostate cancer and associated with disease spread and poor outcome [26,27]. Sun et al. reported that B7-H3 expression was positively correlated with a more advanced tumor grade in colorectal cancer [28]. A recent study from Chen et al. demonstrated that induced expression of B7-H3 on the lung cancer cells and macrophages suppressed T-cell mediating anti-tumor immune response [29]. Furthermore, it is reported that inhibition of B7-H3 by siRNA significantly suppresses cell migration and invasion, enhances sensitivity to chemotherapeutic drugs in acute monocytic leukemia U937 cells [30]. In pancreatic carcinoma, it is suggested that silencing of B7-H3 increases gemcitabine sensitivity through induction of surviving-dependent apoptosis [31]. In our study, the mRNA and protein levels of B7-H3 were remarkably reduced in NSCLC cells treated with cisplatin and astragaloside IV, suggesting that astragaloside IV increased cisplatin sensitivity via downregulating B7-H3 expression. In order to confirm the role of B7-H3 in the chemoresistance, B7-H3 was ectopically expressed in NSCLC cells. Consequently, we found that up-regulation of B7-H3 diminished the sensitization role of astragaloside IV in cellular responses to cisplatin.

In conclusion, our study demonstrates that astragaloside IV treatment increased cisplatin cytotoxicity in NSCLC cells through inhibition of B7-H3 expression. These findings suggest that combined treatment with astragaloside IV and inhibition of B7-H3 are potential therapeutic approach for patients with lung cancer.

**Disclosure Statement**

The authors declare that they have no competing interests.

**References**

He et al.: Astragaloside IV Enhances Chemosensitivity to Cisplatin in NSCLC

© 2016 The Author(s). Published by S. Karger AG, Basel
www.karger.com/cpb


